Tags

Type your tag names separated by a space and hit enter

Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo.
Int J Dermatol. 2005 Sep; 44(9):736-42.IJ

Abstract

BACKGROUND

Recently, it has been shown that UVB phototherapy may be more effective than UVA in the treatment of vitiligo. Currently, however, no studies have compared the efficacy of UVB311 nm and broad-band UVB therapy. Calcipotriol has recently been reported to be effective adjunctive treatment for vitiligo, enhancing the efficacy of 8-methoxypsoralen plus UVA (PUVA) therapy.

METHODS

Ten patients were enrolled in the study; nine completed the 12 months of therapy. The upper part of the body was treated twice weekly with UVB311 nm and the lower part with broad-band UVB. Calcipotriol was applied onto the vitiligo lesions of the right side of the body and placebo on the left side. Repigmentation was documented by photography, planimetry, and Vitiligo Disease Activity (VIDA) score. The quality of life was measured by the Dermatology Life Quality Index (DLQI).

RESULTS

After 7-16 weeks, six of the nine patients showed initial repigmentation on the side treated with UVB311 nm. After 6 months of treatment, none of the patients showed repigmentation on the areas treated with broad-band UVB, which prompted us to apply UVB311 nm all over the body. At the end of 12 months, two patients showed > 75% repigmentation, two showed 51-75%, two showed 26-50%, and three showed 0-25%. In all patients with progressive vitiligo (seven of the nine patients), disease activity was stopped. Remarkably, vitiligo lesions treated with calcipotriol initially showed delayed repigmentation compared with control areas; however, there was no therapeutic difference between calcipotriol and placebo, both in combination with UVB311 nm, by the end of the study. The DLQI score improved significantly by an average of 28%. Conclusion UVB311 nm therapy was effective in the treatment of vitiligo, whereas broad-band UVB had no effect. Combination with calcipotriol ointment was not superior to UVB311 nm monotherapy. The quality of life significantly improved with narrow-band UVB311 nm phototherapy.

Authors+Show Affiliations

Department of Dermatology, University of Würzburg, Germany. Hartmann_a@klinik.uni-wuerzburg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

16135141

Citation

Hartmann, Anke, et al. "Narrow-band UVB311 Nm Vs. Broad-band UVB Therapy in Combination With Topical Calcipotriol Vs. Placebo in Vitiligo." International Journal of Dermatology, vol. 44, no. 9, 2005, pp. 736-42.
Hartmann A, Lurz C, Hamm H, et al. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol. 2005;44(9):736-42.
Hartmann, A., Lurz, C., Hamm, H., Bröcker, E. B., & Hofmann, U. B. (2005). Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. International Journal of Dermatology, 44(9), 736-42.
Hartmann A, et al. Narrow-band UVB311 Nm Vs. Broad-band UVB Therapy in Combination With Topical Calcipotriol Vs. Placebo in Vitiligo. Int J Dermatol. 2005;44(9):736-42. PubMed PMID: 16135141.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. AU - Hartmann,Anke, AU - Lurz,Christa, AU - Hamm,Henning, AU - Bröcker,Eva-B, AU - Hofmann,Uta B, PY - 2005/9/2/pubmed PY - 2005/12/22/medline PY - 2005/9/2/entrez SP - 736 EP - 42 JF - International journal of dermatology JO - Int J Dermatol VL - 44 IS - 9 N2 - BACKGROUND: Recently, it has been shown that UVB phototherapy may be more effective than UVA in the treatment of vitiligo. Currently, however, no studies have compared the efficacy of UVB311 nm and broad-band UVB therapy. Calcipotriol has recently been reported to be effective adjunctive treatment for vitiligo, enhancing the efficacy of 8-methoxypsoralen plus UVA (PUVA) therapy. METHODS: Ten patients were enrolled in the study; nine completed the 12 months of therapy. The upper part of the body was treated twice weekly with UVB311 nm and the lower part with broad-band UVB. Calcipotriol was applied onto the vitiligo lesions of the right side of the body and placebo on the left side. Repigmentation was documented by photography, planimetry, and Vitiligo Disease Activity (VIDA) score. The quality of life was measured by the Dermatology Life Quality Index (DLQI). RESULTS: After 7-16 weeks, six of the nine patients showed initial repigmentation on the side treated with UVB311 nm. After 6 months of treatment, none of the patients showed repigmentation on the areas treated with broad-band UVB, which prompted us to apply UVB311 nm all over the body. At the end of 12 months, two patients showed > 75% repigmentation, two showed 51-75%, two showed 26-50%, and three showed 0-25%. In all patients with progressive vitiligo (seven of the nine patients), disease activity was stopped. Remarkably, vitiligo lesions treated with calcipotriol initially showed delayed repigmentation compared with control areas; however, there was no therapeutic difference between calcipotriol and placebo, both in combination with UVB311 nm, by the end of the study. The DLQI score improved significantly by an average of 28%. Conclusion UVB311 nm therapy was effective in the treatment of vitiligo, whereas broad-band UVB had no effect. Combination with calcipotriol ointment was not superior to UVB311 nm monotherapy. The quality of life significantly improved with narrow-band UVB311 nm phototherapy. SN - 0011-9059 UR - https://www.unboundmedicine.com/medline/citation/16135141/Narrow_band_UVB311_nm_vs__broad_band_UVB_therapy_in_combination_with_topical_calcipotriol_vs__placebo_in_vitiligo_ L2 - https://doi.org/10.1111/j.1365-4632.2004.02154.x DB - PRIME DP - Unbound Medicine ER -